

# AZ960

Cat. No.: HY-10411 905586-69-8 CAS No.: Molecular Formula: C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N<sub>6</sub> Molecular Weight: 354.36

Target: JAK; Apoptosis; Parasite; Virus Protease

Pathway: Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt;

Apoptosis; Anti-infection

Storage: Powder -20°C 3 years

> 4°C 2 years

-80°C 2 years In solvent

-20°C 1 year

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: ≥ 30 mg/mL (84.66 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8220 mL	14.1099 mL	28.2199 mL
	5 mM	0.5644 mL	2.8220 mL	5.6440 mL
	10 mM	0.2822 mL	1.4110 mL	2.8220 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	AZ960 is a potent and specific inhibitor of the JAK2 kinase with a $K_i$ of 0.45 nM.				
IC <sub>50</sub> & Target	JAK2 0.45 nM (Ki)	JAK2 <3 nM (IC <sub>50</sub> )	JAK3 9 nM (IC <sub>50</sub> )		
In Vitro	AZ960 inhibits Jak2 kinase with a $K_i$ of 0.45 nM. Z960 possesses much less potent activity against Jak1, 3, and TYK2. AZ960 is active against other kinases, including TrkA, Aurora-A, and FAK, with IC <sub>50</sub> of around 0.1 $\mu$ M. AZ960 effectively induces growth				

arrest and apoptosis of human T-cell lymphotropic virus type 1, HTLV-1-infected T cells (MT-1 and MT-2) in parallel with

downregulation of the phosphorylated forms of Jak2 and Bcl-2 family proteins including Bcl-2 and Mcl- $1^{[2]}$ . AZ960 potently inhibits the clonogenic growth and induces apoptosis of freshly isolated acute myelogenous leukemia cells from patients in association with cleavage of caspase 3 and down regulation of anti-apoptotic Bcl-xL proteins<sup>[1]</sup>. AZ960 has a K<sub>i</sub> of 1.25  $\mu$ M for T. brucei extracellular signal-regulated kinase 8 (TbERK8). It inhibits TbERK8 with an IC<sub>50</sub> of 120 nM<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **PROTOCOL**

Cell Assay [2]

AZ960 is dissolved in 100% DMSO to a 0.01 M. HTLV-1-infected T cells and MOLT-4 cells are cultured with various concentrations of AZ960 (0.03-1  $\mu$ M) for 2 days in 96-well plates. Peripheral blood lymphocytes are activated by phytohemagglutinin (PHA; 5 ng/mL) for 1 hour, then cultured with various concentrations of AZ960 (0.03–1  $\mu$ M) for 2 days in 96-well plates. After culture, cell number and viability are evaluated by measuring the mitochondrial-dependent conversion of the MTT to a colored formazan product<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Ikezoe T, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011 Nov 15;129(10):2512-21.

[2]. Yang J, et al. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Mol Cancer Ther. 2010 Dec;9(12):3386-95.

[3]. Valenciano AL, et al. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor. Bioorg Med Chem. 2016 Oct 1;24(19):4647-51.

[4]. Gozgit JM, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43.

Caution: Product has not been fully validated for medical applications. For research use only.

E-mail: tech@MedChemExpress.com

Tel: 609-228-6898 Fax: 609-228-5909

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA